Retatrutide Once Weekly for Pain Management and Weight Loss in Adults with Knee Osteoarthritis and Obesity: A Clinical Review

Highlights

  • Retatrutide, a triple receptor agonist targeting GIP, GLP-1, and glucagon receptors, provides significant analgesic benefits in adults with knee osteoarthritis and obesity.
  • Phase 3 TRIUMPH-4 and TRIUMPH-1-OA trials demonstrate robust reductions in WOMAC pain scores and body weight up to 80 weeks with once-weekly subcutaneous retatrutide.
  • Weight loss achieved surpasses 20% on average, which likely contributes synergistically to pain relief and functional improvement.
  • Gastrointestinal adverse events were common, and serious adverse events were more frequent with retatrutide than placebo, emphasizing the need for careful safety monitoring.

Background

Specialty calculators

Browse calculators

For clinical reference; use professional judgment.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply